These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 3014083)

  • 1. A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas.
    Moertel CG; Rubin J; O'Connell MJ; Schutt AJ; Wieand HS
    J Clin Oncol; 1986 Jul; 4(7):1053-7. PubMed ID: 3014083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Combination chemotherapy of cis-diamminedichloroplatinum (CDDP) and 5-fluorouracil (5-FU) in gastrointestinal tumors].
    Yamazaki H; Ogawa M; Horikoshi N; Inoue K; Nakamura T; Ueno K; Ito Y; Imajo K; Mukaiyama T; Miyaoka K
    Gan To Kagaku Ryoho; 1986 Aug; 13(8):2568-72. PubMed ID: 3017230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy in gastrointestinal cancer.
    Reitemeier RJ; Moertel CG; Hahn RG
    Cancer Res; 1970 May; 30(5):1425-8. PubMed ID: 4246651
    [No Abstract]   [Full Text] [Related]  

  • 4. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin.
    Cullinan S; Moertel CG; Wieand HS; Schutt AJ; Krook JE; Foley JF; Norris BD; Kardinal CG; Tschetter LK; Barlow JF
    Cancer; 1990 May; 65(10):2207-12. PubMed ID: 2189551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach.
    Cazap EL; Gisselbrecht C; Smith FP; Estevez RA; Alvarez CA; Lagarde C; Hannois A; Ahmed S; Schein PS; Woolley PV
    Cancer Treat Rep; 1986 Jun; 70(6):781-3. PubMed ID: 3524826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
    Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research.
    De Lisi V; Cocconi G; Angelini F; Cavicchi F; Di Costanzo F; Gilli G; Rodinò C; Soldani M; Tonato M; Finardi C
    Cancer; 1996 Jan; 77(2):245-50. PubMed ID: 8625230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral administration of fluorouracil. A preliminary trial.
    Nadler SH
    Arch Surg; 1968 Oct; 97(4):654-6. PubMed ID: 5678137
    [No Abstract]   [Full Text] [Related]  

  • 9. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group.
    J Clin Oncol; 1986 Dec; 4(12):1794-8. PubMed ID: 2946815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
    Jiang Y; Qiu XH; Yang YX; Zhang SQ; Chen ZM
    Ai Zheng; 2006 Aug; 25(8):1029-34. PubMed ID: 16965688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma.
    Kim YH; Shin SW; Kim BS; Kim JH; Kim JG; Mok YJ; Kim CS; Rhyu HS; Hyun JH; Kim JS
    Cancer; 1999 Jan; 85(2):295-301. PubMed ID: 10023695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma.
    Chung YS; Yamashita Y; Inoue T; Matsuoka T; Nakata B; Onoda N; Maeda K; Sawada T; Kato Y; Shirasaka T; Sowa M
    Cancer; 1997 Jul; 80(1):1-7. PubMed ID: 9210702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
    Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
    Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma. The North Central Cancer Treatment Group.
    Moertel CG; Gunderson LL; Mailliard JA; McKenna PJ; Martenson JA; Burch PA; Cha SS
    J Clin Oncol; 1994 Jan; 12(1):21-7. PubMed ID: 8270979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
    Gu Y; Shu Y; Xu Q
    Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer.
    Okabe S; Ishikawa T; Tanami H; Kuwabara H; Fukahara T; Udagawa M; Ootsukasa S; Arai T; Maruyama S; Murase N; Yamashita H; Iwai T
    J Med Dent Sci; 2002 Jun; 49(2):77-84. PubMed ID: 12627817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
    Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
    Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adriamycin (NSC-123127) therapy for advanced gastrointestinal cancer.
    Frytak S; Moertel CG; Schutt AJ; Hahn RG; Reitemeier RJ
    Cancer Chemother Rep; 1975; 59(2 Pt 1):405-9. PubMed ID: 1097099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus.
    Kulke MH; Wu B; Clark JW; Enzinger PC; Lynch TJ; Vincitore M; Michelini A; Fuchs CS
    Cancer Invest; 2006; 24(3):229-34. PubMed ID: 16809148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.